Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: Results of the HIT-gBM-c protocol

Cancer

Volumn 116, Issue 3, 2010, Pages 705-712

  Wolff, Johannes E A ^a,b   Driever, Pablo Hernaiz ^c   Erdlenbruch, Bernhard ^d   Kortmann, Rolf D ^e   Rutkowski, Stefan ^f   Pietsch, Torsten ^g   Parker, Crystal ^a   Metz, Monica Warmuth ^f   Gnekow, Astrid ^h   Kramm, Christof M ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Regensburg   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Hospital of Minden   (United States)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h UNIVERSITY HOSPITAL AUGSBURG   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Chemotherapy; Children; Diffuse intrinsic pontine glioma; Glioblastoma; Resection

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VALPROIC ACID; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; GLIOMA; HUMANS; MALE; TREATMENT OUTCOME;

EID: 76249092138     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24730     Document Type: Article

References (45)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol. 1997;39:376-379.
3. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer. 1998;78:652-661.
4. Liu L, Vapiwala N, Munoz LK, et al. A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Med Pediatr Oncol. 2001;37:390-392.
5. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9:197-206.
6. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Children's Cancer Study Group. J Neurooncol. 1989;7:165-177.
7. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110:1542-1550.
8. Hauch H, Sajedi M, Wolff JE. Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res. 2005;25:3585-3590.
9. Wolff JE, Berrak S, Koontz Webb SE, Zhang M. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24,193 patients. J Neurooncol. 2008;88:57-63.
10. Wolff JE, Classen CF, Wagner S, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol. 2008;87:155-164.
11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
12. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
13. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg. 1998;89:52-59.
14. Kramm CM, Wagner S, Van Gool S, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res. 2006;26:3773-3779.
15. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420-427.
16. Zhang M, Segerer F, Ketonen L, Mahajan A, Wolff J. Prediction of tumour regrowth of pontine glioma using a 2-term model. Anticancer Res. 2008;28:741-749.
17. Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79:281-287.
18. Wolff JE, Boos J, Krahling KH, Jurgens H. Second temporal remission in a malignant glioma with trophosphamide and etoposide: a case report. Klin Padiatr. 1996;208:190-192.
19. Wolff JE, Boos J, Kuhl J. [HIT-GBM: multicenter study of treatment of children with malignant glioma]. Klin Padiatr. 1996;208:193-196.
20. Wolff JE, Molenkamp G, Westphal S, et al. Oral trophosphamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000;89:2131-2137.
21. Wolff JE, Westphal S, Molenkamp G, et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer. 2002;87:945-949.
22. Wolff JE, Wagner S, Sindichakis M, et al. Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a phase I study. Anticancer Res. 2002;22:3569-3572.
23. Knupfer MM, Poppenborg H, Van Gool S, Domula M, Wolff JE. Interferon-gamma inhibits proliferation and adhesion of T98G human malignant glioma cells in vitro. Klin Padiatr. 1997;209:271-274.
24. Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79:315-321.
25. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008;90:309-314.
26. Wolff JE, Egeler RM, Anderson R, Ujack E, Iceton S, Coppes MJ. Mesna inactivates platinum agents in vitro. Anticancer Res. 1998;18:4077-4081.
27. Kangarloo SB, Gangopadhyay SB, Syme RM, Wolff JE, Gluck S. Influence of mesna on the pharmacokinetics of cis-platin and carboplatin in pediatric cancer patients. Med Oncol. 2004;21:9-20.
28. Driever PH, Knupfer MM, Cinatl J, Wolff JE. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr. 1999;211:323-328.
29. Wagner S, Csatary CM, Gosztonyi G, et al. Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. Apmis. 2006;114:731-743.
30. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer. 2004;43:181.
31. Gnekow AK. Recommendations of the Brain Tumor Sub-committee for the reporting of trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology. Med Pediatr Oncol. 1995;24:104-108.
32. Amini E, Roffidal T, Lee A, et al. Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. Pediatr Blood Cancer. 2008;51:137-140.
33. Wolff JE, Gnekow AK, Kortmann RD, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94:264-271.
34. Chastagner P, Kalifa C, Doz F, et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer. 2007;49:803-807.
35. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer. 2005;104:2862-2871.
36. Claes A, Schuuring J, Boots-Sprenger SM, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 2008;18:423-433.
37. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27:2897-2909.
38. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26:2466-2474.
39. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective. J Neurooncol. 2005;75:253-266.
40. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006;76:313-319.
41. Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007;13(22 pt 1):6712-6718.
42. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42:2335-2342.
43. Massimino M, Gandola L, Luksch R, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol. 2005;7:41-48.
44. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91:1656-1662.
45. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-3104.